舒血宁与尼莫地平联用治疗椎基底动脉供血不足性眩晕

Clinical Observation of Teponin Combined with Nimodipine on 42 Vertigo Patients of Vertebrobasilar Insufficiency

目的:评价舒血宁注射液(银杏叶提取物)与尼莫地平联用对椎基底动脉供血不足(VB I)性眩晕的临床效果。方法:对42例VB I性眩晕采用舒血宁注射液+尼莫地平治疗。14天后观察患者临床症状、血液流变学改善情况及经颅多普勒(TCD)血流动力学改变。结果:①经两药联用治疗总有效率为90.48%;②治疗后血液流变学指标全血比黏度高切、全血比黏度低切及血浆比黏度值分别为(4.36±0.88)、(8.75±1.31)及(1.02±0.24)mPa.s,比治疗前测定值(6.69±1.78)、(9.75±1.78)及(1.85±0.30)mPa.s明显降低,差异具有非常显著性的意义(P<0.01);③治疗后血流动力学指标左椎动脉(LVA)、右椎动脉(RVA)及基底动脉(BA)收缩期血液最大流速分别为(42.79±6.09)、(42.82±5.33)及(51.70±4.78)cm/s,比治疗前测定值(36.46±4.84)、(35.85±4.86)及(43.50±4.50)cm/s明显升高,差异具有非常显著性的意义(P<0.01)。结论:舒血宁和尼莫地平联用治疗VB I性眩晕疗效明显,不良反应轻微。

Objective：To evaluate the Teponin and Nimodipine in the treatment of vertebrobasilar insufficiency （ VBI）. Methods：42 VBI patients were treated with Teponin and Nimodipine. 14 days after the treatment clinical symptoms, hemorheology and transocranial Doppler （TCD） on the patients were observed. Results：The efficacy rate was 90.48%. After treatment, the level of hemorheology （4.36 ±0.88）, （8.75 ±1.31）,（1.02 ±0.24） mPa · s were significantly less than that before treatment （6.69 ± 1.78）, （9.75 ± 1.78）, （1.85 ± 0.30 ）mPa · s （P 〈 0.01 ）. And all of the transoeranial Doppler（TCD） （42.79 ± 6.09 ） , （42.82 ± 5.33 ） , （51.70 ± 4.78 ）cm/s were significantly higher than that before treatment（ 36.46 ± 4.84 ） , （ 35.85 ± 4.86 ）, （43.50 ± 4.50 ） cm/s （ P 〈 0.01 ）. Conclusion ： Teponin com- bined with Nimodipine on vertigo patients of vertebrobasilar insufficiency shows obvious curing effectiveness.